Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator of DNA damage checkpoint protein 1 (MDC1) is a large nuclear scaffold/adaptor protein essential for cellular responses to DNA double-strand breaks. It contains an N-terminal forkhead-associated (FHA) domain, two BRCA1 C-terminal (BRCT) motifs, and a central tandem repeat region. MDC1 directly binds phosphorylated histone H2AX (γH2AX) at sites of DNA damage, assembling and retaining DNA damage response (DDR) and repair proteins, and is critical for activation of the intra-S phase and G2/M cell cycle checkpoints. It coordinates downstream recruitment and activation of kinases like ATM, CHEK1, and CHEK2 and helps stabilize and regulate p53 activity. Loss or dysfunction of MDC1 causes radiosensitivity, impaired DNA damage checkpoints, defects in homologous recombination, and tumor susceptibility[2][4][6]. There are no current therapies directly targeting MDC1, but its role in DNA repair makes it a potential biomarker and research target for cancer and other genomic instability disorders.
Not applicable; no direct drugs currently approved. Mechanistically, targeting MDC1 would likely modulate DNA repair and checkpoint response pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator of DNA damage checkpoint protein 1 (MDC1).